Semaglutide can: Semaglutide is available as a daily oral pill or a weekly injectable medication
Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions
not been studied in any retatrutide clinical trial
5 Protein is the highest-priority category because 20-40% of weight loss on GLP-1 medications comes from lean muscle mass, creating genuine clinical demand alongside behavioral preference
In practice, this often includes women with obesity (e.g., BMI 30 kg/m 2 )or those close to this threshold with clinically meaningful IR and/or metabolic comorbidities such as MASLD or impaired glucose tolerancewho have a defined plan for conception or ART within the next year
Insurance coverage decisions typically require demonstration of obesity through BMI thresholds with or without metabolic comorbidities but do not specifically require established cardiovascular disease